Silvio Danese to Male
This is a "connection" page, showing publications Silvio Danese has written about Male.
Connection Strength
0.213
-
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7.
Score: 0.011
-
Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. Curr Drug Targets. 2019; 20(13):1339-1348.
Score: 0.011
-
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
Score: 0.011
-
Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 2019; 10(2):149-158.
Score: 0.011
-
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029.
Score: 0.011
-
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018 Mar; 30(3):316-322.
Score: 0.010
-
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):601-606.
Score: 0.010
-
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 2019 01; 68(1):40-48.
Score: 0.010
-
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. Minerva Gastroenterol Dietol. 2017 Dec; 63(4):319-326.
Score: 0.010
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.010
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.010
-
Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017 Mar; 11(3):203-214.
Score: 0.009
-
Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013 Oct; 38(7):741-51.
Score: 0.007
-
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005 Apr; 100(4):886-95.
Score: 0.004
-
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology. 2021 06; 160(7):2435-2450.e34.
Score: 0.003
-
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. Pharmacol Res. 2020 10; 160:105061.
Score: 0.003
-
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. Clin Gastroenterol Hepatol. 2020 09; 18(10):2366-2368.e3.
Score: 0.003
-
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 07; 69(7):1213-1217.
Score: 0.003
-
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1361-1369.
Score: 0.003
-
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214.
Score: 0.003
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1215-1226.
Score: 0.003
-
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
Score: 0.003
-
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019 08 15; 79(16):4196-4210.
Score: 0.003
-
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. J Crohns Colitis. 2019 Mar 30; 13(4):417-423.
Score: 0.003
-
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018 Nov 09; 12(10):1180-1190.
Score: 0.003
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.003
-
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
Score: 0.003
-
TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice. J Crohns Colitis. 2018 Jan 24; 12(2):230-244.
Score: 0.003
-
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783.
Score: 0.003
-
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2018 04; 154(5):1334-1342.e4.
Score: 0.003
-
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 12 23; 390(10114):2779-2789.
Score: 0.003
-
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27; 11(11):1317-1325.
Score: 0.002
-
Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
Score: 0.002
-
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929.
Score: 0.002
-
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
Score: 0.002
-
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144.
Score: 0.002
-
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736.
Score: 0.002
-
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
Score: 0.002
-
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017 Jul; 153(1):77-86.e6.
Score: 0.002
-
Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
Score: 0.002
-
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
Score: 0.002
-
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
Score: 0.002
-
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. J Crohns Colitis. 2015 Jul; 9(7):541-7.
Score: 0.002
-
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5.
Score: 0.002